Ciprofloxacin

# Ciprofloxacin ## Overview - **Classification**: Fluoroquinolone antibiotic. - **Mechanism**: Inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. ## Primary Indications 1. **Complicated Urinary Tract Infections (UTI)/Pyelonephritis**: Broad-spectrum coverage for resistant uropathogens. 2. **Intra-abdominal Infections**: Often used in combination for mixed infections. 3. **Bone and Joint Infections**: Effective against Gram-negative bacteria and some Gram-positives. 4. **Infectious Diarrhea**: Traveler's diarrhea, E. coli, Shigella, Campylobacter. 5. **Anthrax (Post-Exposure & Treatment)**: Critical agent for Bacillus anthracis. ## Adult Dosing ### Standard Dosing **Complicated UTI / Pyelonephritis** - **Dose**: **500 mg** - **Frequency**: Every 12 hours - **Route**: Oral (PO) - **Duration**: 7-14 days (or as per guidelines) **Intra-abdominal Infections (e.g., complicated)** - **Dose**: **500 mg** PO or **400 mg** IV - **Frequency**: Every 12 hours - **Route**: PO or IV - **Duration**: 7-14 days **Bone and Joint Infections** - **Dose**: **500-750 mg** PO or **400 mg** IV - **Frequency**: Every 12 hours (PO) or Every 8-12 hours (IV) - **Route**: PO or IV - **Duration**: 4-6 weeks or longer ### Dose Adjustments - **Renal Impairment**: CrCl 30-50 mL/min: Standard dose, extended interval to Q18-24H. - CrCl <30 mL/min (including dialysis): **250-500 mg** Q24H (PO) or **200-400 mg** Q24H (IV). - **Hepatic Impairment**: Generally no dose adjustment needed for mild-moderate impairment. - Use with caution in severe hepatic dysfunction. - **Elderly Patients**: Consider age-related decline in renal function for dosing. ## Pediatric Dosing *Ciprofloxacin is generally reserved for pediatric patients when the benefit outweighs the risk of arthropathy observed in juvenile animals. It is not a first-line agent for most common pediatric infections.* ### Neonates (0-28 days) - **Dose**: Not routinely recommended due to limited data and potential for arthropathy. - **Frequency**: If used for severe, resistant infections, under expert guidance, typical doses are **10 mg/kg** IV/PO. - **Maximum**: No established maximum for neonates. - **Special Notes**: Use only when no other suitable options exist; consider monitoring for joint-related adverse effects. ### Infants (1-12 months) - **Dose**: For specific severe indications (e.g., anthrax, complicated UTI/pyelonephritis): **10-15 mg/kg** IV/PO. - **Frequency**: Every 12 hours. - **Maximum**: **400 mg/dose** IV; **750 mg/dose** PO. - **Special Notes**: Reserve for infections where other options are ineffective or contraindicated. ### Children (1-12 years) - **Complicated UTI/Pyelonephritis**: **10-20 mg/kg** PO/IV. - **Cystic Fibrosis Exacerbations**: **20 mg/kg** PO or **30 mg/kg** IV. - **Anthrax**: **10-15 mg/kg** PO/IV. - **Frequency**: Every 12 hours for all indications. - **Maximum**: **750 mg/dose** PO; **400 mg/dose** IV. Max daily **1.5 g** PO, **800 mg** IV. ### Adolescents (13-18 years) - **Dose**: Generally use adult dosing once skeletally mature and weight is equivalent. - **Maximum**: Follow adult maximum doses. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to ciprofloxacin or other fluoroquinolones. - **Absolute**: Concomitant use with Tizanidine (due to severe hypotension and somnolence). - **Relative**: History of Myasthenia Gravis (may exacerbate muscle weakness). ### Common Adverse Effects - **Very Common (>10%)**: Nausea, diarrhea. - **Common (1-10%)**: Headache, dizziness, insomnia, abdominal pain, rash, elevated liver enzymes. - **Serious but Rare**: Tendinitis/tendon rupture (especially Achilles), peripheral neuropathy, QTc prolongation/arrhythmias, *Clostridioides difficile* infection (CDI), hypoglycemia/dysglycemia, psychiatric effects, aortic dissection/aneurysm. ### Key Drug Interactions - **Polyvalent Cations (Mg, Al, Ca, Fe, Zn, dairy)**: Reduce ciprofloxacin absorption. Separate administration by **at least 2 hours before or 6 hours after**. - **Theophylline**: Increases theophylline plasma levels, leading to toxicity. Monitor theophylline levels closely. - **Warfarin**: Enhances anticoagulant effect. Monitor INR frequently. - **Methotrexate**: May increase methotrexate levels, leading to toxicity. Monitor for adverse effects. - **Tizanidine**: **Contraindicated**. Significant hypotension and somnolence. - **QTc prolonging drugs**: Increased risk of Torsades de Pointes. Avoid concurrent use if possible. ## Monitoring & Follow-up - **Before Treatment**: Assess renal function (CrCl). - **During Treatment**: Monitor for signs of tendon pain/swelling, peripheral neuropathy, C. difficile symptoms. - In diabetic patients, monitor blood glucose closely. - If QTc risk factors, consider baseline and follow-up ECG. - **Clinical Signs**: Instruct patients to report tendon pain, numbness/tingling, or persistent diarrhea immediately. ## Clinical Pearls - 💡 **Tip 1**: Counsel patients on the risk of tendon rupture; advise immediate discontinuation and medical attention for new pain or swelling in tendons/joints. - 💡 **Tip 2**: Advise patients to avoid taking ciprofloxacin with dairy products, antacids, or mineral supplements due to significant reduction in absorption. - 💡 **Tip 3**: Emphasize importance of adequate hydration to prevent crystalluria. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.